|
US5024842A
(en)
*
|
1988-04-28 |
1991-06-18 |
Alza Corporation |
Annealed coats
|
|
US5126146A
(en)
*
|
1989-10-23 |
1992-06-30 |
Merck & Co., Inc. |
Cellulosic coating
|
|
US5643591A
(en)
*
|
1991-01-16 |
1997-07-01 |
Fmc Corporation |
Solid dosage forms
|
|
EP0567541B1
(de)
*
|
1991-01-16 |
1998-10-07 |
Fmc Corporation |
Träger für wirkstoffe und damit hergestellte feste darreichungsformen
|
|
US5178867A
(en)
*
|
1991-08-19 |
1993-01-12 |
Alza Corporation |
Dosage form for delivering drug in short-time period
|
|
GB9311191D0
(en)
*
|
1993-05-29 |
1993-07-14 |
Danbiosyst Uk |
Controlled release drug formulation
|
|
GB9609094D0
(en)
*
|
1996-05-01 |
1996-07-03 |
Univ Strathclyde |
Delivery device
|
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
|
PT1014951E
(pt)
*
|
1997-09-09 |
2005-03-31 |
Alza Corp |
Composicao de revestimento farmaceutica e metodo para a sua utilizacao
|
|
US6514530B2
(en)
*
|
1997-09-09 |
2003-02-04 |
Alza Corporation |
Dosage form comprising means for changing drug delivery shape
|
|
US7060734B1
(en)
|
1997-09-09 |
2006-06-13 |
Alza Corporation |
Pharmaceutical coating composition and method of use
|
|
IN186245B
(de)
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
|
WO1999029297A1
(en)
*
|
1997-12-05 |
1999-06-17 |
Alza Corporation |
Osmotic dosage form comprising first and second coats
|
|
KR100576583B1
(ko)
*
|
1997-12-22 |
2006-05-04 |
알자 코포레이션 |
서방성 약물 송달 장치용 속도 조절막
|
|
US6706282B1
(en)
|
1998-11-02 |
2004-03-16 |
Evangeline Cruz |
Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
|
|
HK1039456A1
(zh)
*
|
1998-11-02 |
2002-04-26 |
Alza Corporation |
有效药剂的控制输送
|
|
US6342249B1
(en)
|
1998-12-23 |
2002-01-29 |
Alza Corporation |
Controlled release liquid active agent formulation dosage forms
|
|
US6635281B2
(en)
|
1998-12-23 |
2003-10-21 |
Alza Corporation |
Gastric retaining oral liquid dosage form
|
|
JP3672008B2
(ja)
*
|
1999-01-20 |
2005-07-13 |
シオノギクオリカプス株式会社 |
硬質カプセル及びその製造方法
|
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
|
US6500462B1
(en)
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
|
US6932861B2
(en)
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
|
AU2002225763A1
(en)
|
2000-11-28 |
2002-06-11 |
Fmc Corporation |
Edible pga(propylene glycol alginate) coating composition
|
|
GB0114746D0
(en)
*
|
2001-06-16 |
2001-08-08 |
Boots Co Plc |
Medicinal composition
|
|
JP4848101B2
(ja)
*
|
2001-08-17 |
2011-12-28 |
株式会社フジモト・コーポレーション |
徐放性マイクロペレット
|
|
US20030185882A1
(en)
*
|
2001-11-06 |
2003-10-02 |
Vergez Juan A. |
Pharmaceutical compositions containing oxybutynin
|
|
US8329217B2
(en)
*
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
|
JP4031232B2
(ja)
*
|
2001-11-09 |
2008-01-09 |
カプスゲル・ジャパン株式会社 |
新規カプセル
|
|
HUP0402661A3
(en)
*
|
2001-12-19 |
2008-04-28 |
Alza Corp |
Formulation and dosage form for the controlled delivery of therapeutic agents
|
|
NZ533060A
(en)
*
|
2001-12-19 |
2006-03-31 |
Alza Corp |
Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
|
|
JP2005525405A
(ja)
*
|
2002-04-29 |
2005-08-25 |
アルザ・コーポレーシヨン |
オキシコドンを制御して補給する方法および剤型
|
|
NZ536693A
(en)
*
|
2002-05-31 |
2007-01-26 |
Alza Corp |
Controlled release dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
|
|
AR039744A1
(es)
*
|
2002-06-26 |
2005-03-09 |
Alza Corp |
Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
|
|
US20040115262A1
(en)
*
|
2002-07-29 |
2004-06-17 |
Frank Jao |
Formulations and dosage forms for controlled delivery of topiramate
|
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
|
CH696420A5
(de)
*
|
2002-09-13 |
2007-06-15 |
Mepha Ag |
Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
|
|
UY28057A1
(es)
*
|
2002-10-31 |
2003-12-31 |
Alza Corp |
Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrófobos
|
|
EP1575569B1
(de)
|
2002-12-13 |
2010-09-29 |
Durect Corporation |
Orale darreichungsform mit flüssigen hochviskosen trägersystemen
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
CA2512786A1
(en)
*
|
2003-01-14 |
2004-08-05 |
Alza Corporation |
Methods and dosage forms with modified viscosity layers
|
|
CA2515641A1
(en)
*
|
2003-02-11 |
2004-08-26 |
Alza Corporation |
Methods and dosage forms with modified layer geometry
|
|
EP1653922A2
(de)
*
|
2003-08-06 |
2006-05-10 |
Alza Corporation |
Gleichförmige zuführung von topiramat über einen verlängerten zeitraum mit verbesserter dispersionsformulierung
|
|
CA2536507A1
(en)
*
|
2003-08-22 |
2005-03-10 |
Alza Corporation |
Stepwise delivery of topiramate over prolonged period of time
|
|
EP1701697A2
(de)
*
|
2003-09-02 |
2006-09-20 |
ALZA Corporation |
Neue arzneimittelzusammensetzungen und dosierformen von topiramat
|
|
CA2540056C
(en)
*
|
2003-09-26 |
2015-03-24 |
Alza Corporation |
Controlled release formulations of opioid and nonopioid analgesics
|
|
CA2540050A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Nishit B. Modi |
Osmotic dosage forms for controlled delivery of alprazolam
|
|
ATE504288T1
(de)
*
|
2003-09-26 |
2011-04-15 |
Alza Corp |
Oros-push-stick für die kontrollierte abgabe von wirkstoffen
|
|
WO2005072079A2
(en)
|
2003-09-26 |
2005-08-11 |
Alza Coporation |
Drug coating providing high drug loading and methods for providing the same
|
|
US20070259033A1
(en)
*
|
2003-09-26 |
2007-11-08 |
Evangeline Cruz |
Controlled release formulations exhibiting an ascending rate of release
|
|
CA2545834A1
(en)
*
|
2003-11-14 |
2005-06-02 |
Alza Corporation |
Controlled release of topiramate in liquid dosage forms
|
|
KR20060109481A
(ko)
*
|
2003-12-04 |
2006-10-20 |
화이자 프로덕츠 인코포레이티드 |
바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
|
|
US6984403B2
(en)
*
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
|
BRPI0417348A
(pt)
*
|
2003-12-04 |
2007-03-13 |
Pfizer Prod Inc |
processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
|
|
WO2005053639A2
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Controlled release multiparticulates formed with dissolution enhancers
|
|
RU2331410C2
(ru)
*
|
2003-12-04 |
2008-08-20 |
Пфайзер Продактс Инк. |
Способ получения фармацевтических мультичастиц
|
|
WO2005053652A1
(en)
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
|
|
MXPA06005913A
(es)
*
|
2003-12-04 |
2006-06-27 |
Pfizer Prod Inc |
Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
|
|
CA2547597A1
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Multiparticulate compositions with improved stability
|
|
KR20060123493A
(ko)
*
|
2003-12-23 |
2006-12-01 |
알자 코포레이션 |
제어된 전달을 위한 약물 조성물의 용해도를 증가시키는방법 및 제형
|
|
EP1701706A2
(de)
*
|
2003-12-29 |
2006-09-20 |
Alza Corporation |
Neue arzneimittelzusammensetzungen und dosierformen
|
|
US20050175696A1
(en)
*
|
2003-12-29 |
2005-08-11 |
David Edgren |
Drug granule coatings that impart smear resistance during mechanical compression
|
|
JP2007517063A
(ja)
*
|
2003-12-29 |
2007-06-28 |
アルザ・コーポレーシヨン |
トピラメートの新規な薬剤組成物および剤形
|
|
WO2006007323A2
(en)
*
|
2004-06-28 |
2006-01-19 |
Alza Corporation |
Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
|
|
EP1791520A2
(de)
*
|
2004-08-19 |
2007-06-06 |
Alza Corporation |
Darreichungsformen für nanopartikelwirkstoffformulierungen mit kontrollierter freisetzung und verfahren
|
|
US8541026B2
(en)
*
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
US7959938B2
(en)
|
2005-03-15 |
2011-06-14 |
Intarcia Therapeutics, Inc. |
Polyoxaester suspending vehicles for use with implantable delivery systems
|
|
CA2605180A1
(en)
*
|
2005-04-19 |
2006-10-26 |
Alza Corporation |
Controlled delivery dosage form of tramadol and gabapentin
|
|
CN101291652A
(zh)
*
|
2005-06-29 |
2008-10-22 |
阿尔扎公司 |
对渗透剂型提供降低的干燥时间的半渗透性组合物
|
|
DE102005031577A1
(de)
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
|
AR055099A1
(es)
*
|
2005-07-28 |
2007-08-08 |
Alza Corp |
Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
|
|
EP1912622A2
(de)
*
|
2005-08-04 |
2008-04-23 |
Alza Corporation |
Osmotische dosierungsformen mit halbdurchlässigen membranen mit polymer-mischungen mit verbesserten eigenschaften
|
|
WO2007041079A2
(en)
*
|
2005-09-30 |
2007-04-12 |
Alza Corporation |
Banded controlled release nanoparticle active agent formulation dosage forms and methods
|
|
PL116330U1
(en)
*
|
2005-10-31 |
2007-04-02 |
Alza Corp |
Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
|
|
US20070196487A1
(en)
*
|
2006-02-16 |
2007-08-23 |
Geerke Johan H |
Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
|
|
AU2007266475B2
(en)
|
2006-05-30 |
2009-12-03 |
Intarcia Therapeutics, Inc. |
Two-piece, internal-channel osmotic delivery system flow modulator
|
|
JP5048773B2
(ja)
|
2006-08-09 |
2012-10-17 |
インターシア セラピューティクス,インコーポレイティド |
浸透圧式デリバリーシステム及びピストンアセンブリー
|
|
US20100029788A1
(en)
*
|
2006-09-29 |
2010-02-04 |
John Pelesko |
Wet edible pearlescent film coatings
|
|
EP2099312B1
(de)
*
|
2006-12-14 |
2016-05-04 |
Sensient Colors LLC |
Perlmuttpigmentzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
|
|
US8524749B2
(en)
*
|
2007-02-09 |
2013-09-03 |
Alza Corporation |
Controlled release compositions of tizanidine
|
|
AU2008244523B2
(en)
|
2007-04-23 |
2012-02-16 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
EP2219622A1
(de)
|
2007-12-06 |
2010-08-25 |
Durect Corporation |
Verfahren zur behandlung von schmerzen, arthritischen zuständen oder entzündung im zusammenhang mit einer chronischen erkrankung
|
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
SMT201700583T1
(it)
|
2009-09-28 |
2018-01-11 |
Intarcia Therapeutics Inc |
Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
SG11201406363VA
(en)
|
2012-05-07 |
2014-11-27 |
Bayer Pharma AG |
Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
|
|
JP2016515523A
(ja)
|
2013-03-15 |
2016-05-30 |
デュレクト コーポレーション |
溶解変動性を低減させるためのレオロジー改質剤を有する組成物
|
|
WO2016040650A1
(en)
*
|
2014-09-10 |
2016-03-17 |
University Of Rochester |
Soluble guanylyl cyclase inhibition effects on lymphatic vasculature
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
US10925639B2
(en)
|
2015-06-03 |
2021-02-23 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
|
KR20240037175A
(ko)
|
2016-05-16 |
2024-03-21 |
인타르시아 세라퓨틱스 인코포레이티드 |
글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
MY205229A
(en)
|
2016-07-06 |
2024-10-08 |
Durect Corp |
Oral dosage form with drug composition, barrier layer and drug layer
|
|
MX2019008006A
(es)
|
2017-01-03 |
2019-08-29 |
Intarcia Therapeutics Inc |
Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
|